Clinical trial
Implitapide in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)…
NCT00079859 · Medical Research Laboratories International, Industry · Terminated
Key facts
| NCT number | NCT00079859 |
|---|---|
| Title | Implitapide in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) on Maximal Concurrent Lipid-Lowering Therapy |
| Official title | Safety and Efficacy Study of Implitapide Compared With Placebo in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) on Maximal Concurrent Lipid-Lowering Therapy |
| Lead sponsor | Medical Research Laboratories International, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Familial Hypercholesterolemia |
| Intervention type | Drug |
| Interventions | Implitapide |
| Enrollment | 120 |
| Start date | Oct 1, 2003 |
| Completion | Apr 1, 2005 |
| First posted | Mar 18, 2004 |
| Last update posted | Jun 24, 2005 |
| Countries | Netherlands, Norway, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: